Chinese Population Health and Multimorbidity Study (CPHMS)

The Chinese Population Health and Multimorbidity Study: Baseline Survey, and Follow-up Investigation

The Chinese Population Health and Multimorbidity Study (CPHMS; initially named China Pulmonary Health Study, CPHS) was a large-scale epidemiological survey designed to investigate the pulmonary health of Chinese adults aged 20 years or older leveraging a multistage stratified sampling scheme between 2011 and 2014 in mainland China. Briefly, a total number of 57,779 local residents were recruited from 10 representative provinces and municipalities and were invited to participate in the study. A final number of 50,991 adults who met the major inclusion criteria could be considered in further analyses.

In order to investigate the changes of pulmonary health and disease status (e.g. occurrence and development of chronic respiratory diseases and other important relevant multimorbidities, lung function indices, etc.) and corresponding impact factors in the CPHMS study population, we plan to initiate the first round of follow-up investigation between 2025 and 2027 (planned) , i.e. more than 10 years after the baseline survey.

Study Overview

• Status: Enrolling by invitation
• Conditions: Malignant Tumors; Chronic Respiratory Diseases; Cardiovascular and Cerebrovascular Diseases; Endocrine and Metabolic Diseases; Multimorbidities

• Study Type: Observational
• Enrollment (Estimated): 50991

Contacts and Locations

Study Locations

• China
  • Beijing Municipality
    • Beijing, Beijing Municipality, China, 100029
      • China-Japan Friendship Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

A total number of 50,991 adults aged 20 years or older from 10 representative provinces and municipalities of China participated in the CPHMS baseline survey between 2011 and 2014. In the follow-up investigation, ideally all the baseline participants should be contacted.

Description

Inclusion Criteria:

• (1) the individuals who participated in the CPHMS baseline survey;
• (2) their ID number and phone number are available;
• (3) sign the informed consent.

Exclusion Criteria:

• (1) incapable of taking pre- and post-bronchodilator spirometry tests;
• (2) request to withdraw the informed consent;
• (3) terminate due to medical or ethical considerations judged by the investigators and/or ethics committee.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Occurrence of multimorbidities	Occurrence of chronic respiratory diseases, cardiovascular and cerebrovascular diseases, malignant tumors, and/or metabolic diseases, etc.	Since the year of baseline survey till the year of 2025 and 2027 (the first round of follow-up investigation of CPHMS)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes of lung function, forced expiratory volume in one second (FEV1)	Changes of pre- and post-bronchodilator spirometry test indices, FEV1	Since the year of baseline survey till the year of 2025 and 2027 (the first round of follow-up investigation of CPHMS)
Changes of lung function, forced vital capacity (FVC)	Changes of pre- and post-bronchodilator spirometry test indices, FVC	Since the year of baseline survey till the year of 2025 and 2027 (the first round of follow-up investigation of CPHMS)
Changes of lung function, FEV1/FVC	Changes of pre- and post-bronchodilator spirometry test indices, FEV1/FVC	Since the year of baseline survey till the year of 2025 and 2027 (the first round of follow-up investigation of CPHMS)
Changes of lung function, the percentage of measured FEV1 value to the predicted value (FEV1%pred)	Changes of pre- and post-bronchodilator spirometry test indices, FEV1%pred	Since the year of baseline survey till the year of 2025 and 2027 (the first round of follow-up investigation of CPHMS)

Collaborators and Investigators

• Sponsor: China-Japan Friendship Hospital

Publications and helpful links

General Publications

• Huang K, Yang T, Xu J, Yang L, Zhao J, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, Chen Y, Sun T, Shan G, Lin Y, Xu G, Wu S, Wang C, Wang R, Shi Z, Xu Y, Ye X, Song Y, Wang Q, Zhou Y, Li W, Ding L, Wan C, Yao W, Guo Y, Xiao F, Lu Y, Peng X, Zhang B, Xiao D, Wang Z, Chen Z, Bu X, Zhang H, Zhang X, An L, Zhang S, Zhu J, Cao Z, Zhan Q, Yang Y, Liang L, Tong X, Dai H, Cao B, Wu T, Chung KF, He J, Wang C; China Pulmonary Health (CPH) Study Group. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study. Lancet. 2019 Aug 3;394(10196):407-418. doi: 10.1016/S0140-6736(19)31147-X. Epub 2019 Jun 20.
• Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, Huang K, Yao W, Sun T, Shan G, Yang T, Lin Y, Wu S, Zhu J, Wang R, Shi Z, Zhao J, Ye X, Song Y, Wang Q, Zhou Y, Ding L, Yang T, Chen Y, Guo Y, Xiao F, Lu Y, Peng X, Zhang B, Xiao D, Chen CS, Wang Z, Zhang H, Bu X, Zhang X, An L, Zhang S, Cao Z, Zhan Q, Yang Y, Cao B, Dai H, Liang L, He J; China Pulmonary Health Study Group. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018 Apr 28;391(10131):1706-1717. doi: 10.1016/S0140-6736(18)30841-9. Epub 2018 Apr 9.
• Xiao D, Chen Z, Wu S, Huang K, Xu J, Yang L, Xu Y, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, Yao W, Sun T, Shan G, Yang T, Lin Y, Zhu J, Wang R, Shi Z, Zhao J, Ye X, Song Y, Wang Q, Hou G, Zhou Y, Li W, Ding L, Wang H, Chen Y, Guo Y, Xiao F, Lu Y, Peng X, Zhang B, Wang Z, Zhang H, Bu X, Zhang X, An L, Zhang S, Cao Z, Zhan Q, Yang Y, Liang L, Liu Z, Zhang X, Cheng A, Cao B, Dai H, Chung KF, He J, Wang C; China Pulmonary Health Study Group. Prevalence and risk factors of small airway dysfunction, and association with smoking, in China: findings from a national cross-sectional study. Lancet Respir Med. 2020 Nov;8(11):1081-1093. doi: 10.1016/S2213-2600(20)30155-7. Epub 2020 Jun 26.

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2011
• Primary Completion (Estimated): June 30, 2027
• Study Completion (Estimated): June 30, 2027

Study Registration Dates

• First Submitted: May 30, 2025
• First Submitted That Met QC Criteria: June 10, 2025
• First Posted (Actual): June 18, 2025

Study Record Updates

• Last Update Posted (Actual): March 5, 2026
• Last Update Submitted That Met QC Criteria: March 4, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: Cohort; Multimorbidities; Epidemiological survey; Population medicine
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Nutritional and Metabolic Diseases; Neoplasms; Metabolic Diseases; Cerebrovascular Disorders
• Other Study ID Numbers: 2022-ZHCH330-01 (Other Grant/Funding Number: Chinese Academy of Medical Sciences); 2016YFC1303900 (Other Grant/Funding Number: Ministry of Science and Technology of P. R. China); 201002008 (Other Grant/Funding Number: Ministry of Health of P. R. China); 2023FY100600 (Other Grant/Funding Number: Ministry of Science and Technology of P. R. China)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No